Terug
27
Ook genoteerd als
HKMPF
OTC
Dagbereik
€ 33,05
€ 34,88
52-Weeksbereik
€ 31,80
€ 56,94
Volume
550
50D / 200D Gem.
€ 39,84
/
€ 45,96
Vorige Slotkoers
€ 32,98
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 9,0 | 0,3 |
| P/B | 1,4 | 2,9 |
| ROE % | 16,4 | 3,7 |
| Net Margin % | 12,0 | 3,8 |
| Rev Growth 5Y % | 7,1 | 10,0 |
| D/E | 0,6 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2027 |
€ 0,00
€ 0,00 – € 0,00
|
3,6 B | 0 |
| FY2026 |
€ 0,00
€ 0,00 – € 0,00
|
3,5 B | 0 |
Belangrijkste Punten
Revenue grew 7,08% annually over 5 years — modest growth
ROE of 16,44% — decent returns on equity
Generating 162,38M in free cash flow
P/E of 9,03 — trading at a low valuation
PEG of 0,89 suggests growth is underpriced
Capital efficient — spends only 5,88% of revenue on capex
Groei
Revenue Growth (5Y)
7,08%
Revenue (1Y)7,35%
Earnings (1Y)12,24%
FCF Growth (3Y)-36,60%
Kwaliteit
Return on Equity
16,44%
ROIC11,06%
Net Margin12,00%
Op. Margin18,63%
Veiligheid
Debt / Equity
0,64
Current Ratio1,82
Interest Coverage5,89
Waardering
P/E Ratio
9,03
P/B Ratio1,40
EV/EBITDA7,93
Dividend Yield0,04%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 7,35% | Revenue Growth (3Y) | 8,06% |
| Earnings Growth (1Y) | 12,24% | Earnings Growth (3Y) | 45,63% |
| Revenue Growth (5Y) | 7,08% | Earnings Growth (5Y) | -1,09% |
| Profitability | |||
| Revenue (TTM) | 3,36B | Net Income (TTM) | 402,94M |
| ROE | 16,44% | ROA | 7,11% |
| Gross Margin | 40,04% | Operating Margin | 18,63% |
| Net Margin | 12,00% | Free Cash Flow (TTM) | 162,38M |
| ROIC | 11,06% | FCF Growth (3Y) | -36,60% |
| Safety | |||
| Debt / Equity | 0,64 | Current Ratio | 1,82 |
| Interest Coverage | 5,89 | Dividend Yield | 0,04% |
| Valuation | |||
| P/E Ratio | 9,03 | P/B Ratio | 1,40 |
| P/S Ratio | 1,08 | PEG Ratio | 0,89 |
| EV/EBITDA | 7,93 | Dividend Yield | 0,04% |
| Market Cap | 3,64B | Enterprise Value | 4,96B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3,36B | 3,13B | 2,88B | 2,52B | 2,55B |
| Net Income | 402,94M | 359,00M | 190,00M | 188,00M | 421,00M |
| EPS (Diluted) | 3,62 | 3,22 | 1,72 | 1,68 | 3,62 |
| Gross Profit | 1,34B | 1,42B | 1,41B | 1,24B | 1,30B |
| Operating Income | 625,46M | 612,00M | 367,00M | 282,00M | 582,00M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 5,67B | 5,13B | 4,68B | 4,47B | 4,37B |
| Total Liabilities | 3,07B | 2,81B | 2,47B | 2,32B | 1,91B |
| Shareholders' Equity | 2,59B | 2,31B | 2,20B | 2,14B | 2,45B |
| Total Debt | 1,65B | 1,31B | 1,19B | 1,28B | 846,00M |
| Cash & Equivalents | 328,00M | 188,00M | 205,00M | 270,00M | 426,00M |
| Current Assets | 2,64B | 2,26B | 2,10B | 2,00B | 2,09B |
| Current Liabilities | 1,45B | 1,98B | 1,34B | 1,08B | 1,02B |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#355 of 670
Recente Activiteit
Ingestapt
Contrarian Investing (David Dreman)
Mar 24, 2026